Guardant Health’s oncology portfolio and Shield continue to help with its ongoing growth. It remains exposed to patent ...

BioNTech has billions in cash, and its oncology programs are moving into late-stage clinical trials.

Humacyte, Vera, Maze and Climb Bio will present dialysis-access and kidney-disease findings at ASN Kidney Week.

Guardant Health reported new data from its Shield blood-based colorectal cancer screening test, including modeling and rural clinic results, indicating very high real world adherence and meaningful ...

The Morning Bull - US Market Morning Update Friday, Oct, 16 2026 US stocks look set for a cautious, slightly softer open, ...

Pope Leo XIV is recovering at a Rome hospital after a “successful” surgery to remove a small growth on his lung, according to ...

The American Medical Association (AMA) CPT Editorial Panel approved a new Category I CPT code describing open ablation of pancreatic tumor (s) using IRE, including imaging guidance. The final code ...

Guardant Health's Shield blood test achieved 99% real-world adherence in two rural clinics, far exceeding typical 28-71% ...

Moderna Inc. stocks have been trading up by 4.22 percent after upbeat mRNA pipeline data strengthened investor confidence.

Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that full abstracts from six studies of opamtistomig (LBL-024), its PD-L1/4-1BB bispecific ...

Investigator-sponsored study funded by the French National Cancer Institute (INCa) meets pre-specified primary efficacy success criterion with 61.3% 12-month overall survival. Exploratory Subgroup ...

Along with the trial update, Verastem priced a public offering of roughly 30.94 million shares at $8 each, plus pre-funded ...